Emerging drugs for schizophrenia: an update

  title={Emerging drugs for schizophrenia: an update},
  author={Luisa-Sophie K{\"o}ster and Maren Carbon and Christoph U. Correll},
  journal={Expert Opinion on Emerging Drugs},
  pages={511 - 531}
Introduction: Schizophrenia is one of the most serious mental disorders. Its treatment remains challenging, as existing antipsychotic antidopaminergic medications improve only/predominantly positive symptoms, agitation and aggression but have limited/insignificant efficacy for negative and cognitive symptoms, which strongly affect functional outcome. Therefore, new therapeutic agents are urgently needed that treat aspects of the spectrum of schizophrenia symptomatology and improve functional… 
Glutamatergic agents for schizophrenia: current evidence and perspectives
Because glutamate guides processes of brain development and maturation, clinical research should focus on the at-risk mental state or first-episode psychosis, address cognition and negative symptoms and use monotherapy designs in parallel to augmentation strategies.
Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
In addition to better-tolerated antipsychotics that treat positive symptoms, the authors could see the arrival of the first effective drug for negative symptoms and CIAS, which would strongly facilitate the ultimate goal of recovery in persons with schizophrenia.
Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
The phenomenology, prevalence, assessment, and treatment of negative and cognitive symptoms in patients with schizophrenia is summarized, including pharmacologic and nonpharmacologic management strategies that can be used in clinical care now, as well as pharmacologic approaches that are being tested.
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Additional mechanisms of action and agents require study to improve schizophrenia outcomes for total/positive symptoms with reduced adverse effects, but also cognitive symptoms, negative symptoms, and treatment resistance, the areas of greatest need in schizophrenia currently.
Investigational dopamine antagonists for the treatment of schizophrenia
The expected benefits of the newly developed antagonists may not be great because they offer little enhanced efficacy for negative symptoms, cognition and functional outcomes.
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
Key meta-analytic findings regarding antipsychotic efficacy in the acute treatment of schizophrenia are summarized, including clozapine in treatment-resistant patients and first-episode patients.
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
ITI-007 60 mg was shown to be effective in reducing symptoms in patients with acutely exacerbated schizophrenia, and was associated with minimal safety risk compared to risperidone or placebo for neuromotor disturbances, prolactin changes, weight gain and metabolic abnormalities.
Brilaroxazine (RP5063) Clinical Experience in Schizophrenia: "A New Option to Address Unmet Needs"
Schizophrenia is a condition comprising of both treatment and comorbidity factors that both complicate its management and present multiple unmet needs. Brilaroxazine (RP5063), a dopamine
Using early antipsychotic response to predict treatment outcome in patients with first-episode psychosis
This work demonstrates that the appropriate time point at which to assess early response differs between antipsychotic drugs, and strong early response is associated with decreased rates of extrapyramidal side-effects, and can predict long-term treatment outcome at least 2 years after treatment initiation.


Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials
Experimental therapeutic research for schizophrenia is rapidly expanding and a number of compounds with novel mechanisms of action are demonstrating encouraging evidence for efficacy across a range of symptoms, however, much work still needs to be conducted before these new agents can be considered for routine clinical treatment.
Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.
It is possible that agents that target glutamatergic signaling in the CNS could have efficacy in reducing all major symptom clusters, providing a more comprehensive treatment strategy, and also avoiding some of the adverse effects that are seen with currently available treatments.
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
An update and critical review of the pharmacology and clinical profiles of current antipsychotic drugs and drugs acting on novel targets with potential to be therapeutic agents in the future is provided.
Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.
Evidence suggests that molecules that modulate signaling by the neurotransmitter acetylcholine (ACh) could provide a more comprehensive treatment of schizophrenia than currently prescribed antipsychotics and further research is needed to examine the utility of such compounds as therapeutics.
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
The lack of clearly efficacious pharmacological treatments for the management of negative symptoms represents a significant unmet need, especially considering the importance of these symptoms on patient outcomes, and further research to identify and characterize novel pharmacology treatments is greatly needed.
Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.
The results of aspirin addition to antipsychotic treatment seem promising, as does the addition of NAC and estrogens, and it has to be investigated if the beneficial effects on symptom severity are indeed mediated by their anti-inflammatory aspects.
Past and present progress in the pharmacologic treatment of schizophrenia.
A historical overview of the pharmacologic advances in the treatment of schizophrenia over the past 50 years is presented, followed by a review of the current developments in optimizing the treatment and outcomes in patients with schizophrenia.
What are we looking for in new antipsychotics?
  • C. Correll
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2011
It is hoped that research on drug-specific biomarkers that can predict response in specific patient groups will advance personalized psychiatric care and improve patient outcomes.
[Treatment of cognitive deficits in schizophrenia. Part 2: Pharmacological strategies].
A detailed review of the literature on strategies for the pharmacological treatment of cognitive deficits in schizophrenia is presented, finding the add-on use of substances which directly influence cognitive processes, so-called cognition-enhancing drugs is more promising.
Antidepressants for the negative symptoms of schizophrenia.
The combination of antipsychotic and antidepressant combinations with antipsychotics alone and antidepressants may be effective in treating negative symptoms of schizophrenia, but the amount of information is currently too limited to allow any firm conclusions.